Mar 8, 2021
High-dose, accelerated radiotherapy brings better 2-year overall survival, with no added toxicity
In patients with limited stage, small-cell lung cancer (SCLC), hyperfractionated, accelerated, twice-daily thoracic radiotherapy (60 Gy) was feasible, and higher doses brought about significant improvements in two-year and median overall survival compared with the standard dose and schedule (45 Gy), with no additional toxicities, according to a study published in
“To our knowledge, the two-year overall survival in our trial is the highest reported in trials in limited stage SCLC, including all trials of high-dose, once-daily thoracic radiotherapy, and adds to the evidence suggesting that accelerated, hyperfractionated thoracic radiotherapy is the most effective approach in this disease,” wrote Bjørn Henning Grønberg, MD, of the Norwegian University of Science and Technology, Trondheim, Norway, and colleagues.
Research Article
Genetic associations with temporal shifts in obesity and severe obesity during the obesity epidemic in Norway: A longitudinal population-based cohort (the HUNT Study)
Maria Brandkvist , Roles Conceptualization, Funding acquisition, Methodology, Supervision, Validation, Writing – review & editing
Affiliations Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, Faculty of Nursing and Health Sciences, Nord University, Levanger, Norway Roles Supervision, Validation, Writing – review & editing
Affiliations Children’s Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, Obesity Centre, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway